What Can We Expect After Roche Hldg (OTCMKTS:RHHBY)’s Upgrade By Citigroup?


Roche Hldg (OTCMKTS:RHHBY) Stock Upgrade

In a recent research report distributed to Clients on Wednesday morning, research analysts at the Citigroup equities division boosted shares of Roche Hldg (OTCMKTS:RHHBY) stock from a Neutral to a respectable Buy rating.

Approximately 346,783 shares of stock traded hands. Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) has declined 5.53% since April 29, 2015 and is downtrending. It has underperformed by 5.33% the S&P500.

 What Can We Expect After Roche Hldg (OTCMKTS:RHHBY)'s Upgrade By Citigroup?

Roche Holding AG is a research healthcare company. The company has a market cap of $233.84 billion. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. It has 25.83 P/E ratio. The Company’s Pharmaceuticals Division comprises the two business divisions: Roche Pharmaceuticals and Chugai.

According to Zacks Investment Research, “Roche Holding AG is a research-based, product-focused organization dedicated to the discovery and early clinical development of pharmaceuticals and drugs, fine chemicals and vitamins, fragrances and flavors, diagnostic equipment and liquid crystals. The Company distributes its products throughout Europe, the United States, Asia and Latin America.” Get a free copy of the Zacks research report on Roche Holding Ltd. (ADR) (RHHBY).